# DESCRIPTION

## BACKGROUND OF THE INVENTION

- describe HBV infection
- discuss current treatments for HBV
- highlight need for new treatment options

## BRIEF SUMMARY OF THE INVENTION

- introduce immunogenic compositions and methods
- describe non-naturally occurring nucleic acid molecule
- specify first polynucleotide sequence
- specify second polynucleotide sequence
- describe vector comprising non-naturally occurring nucleic acid molecule
- specify plasmid DNA vector
- describe adenoviral vector
- introduce non-naturally occurring HBV surface antigen
- specify first HBV surface antigen
- specify second HBV surface antigen
- describe host cells comprising non-naturally occurring nucleic acid molecule and/or vector
- introduce composition comprising non-naturally occurring nucleic acid molecule, vector, and/or HBV surface antigen
- describe vaccine combination
- specify first non-naturally occurring nucleic acid molecule
- specify second non-naturally occurring nucleic acid molecule
- describe signal sequence
- specify promoter sequence
- specify enhancer sequence
- specify polyadenylation signal sequence

## DETAILED DESCRIPTION OF THE INVENTION

- incorporate references by citation
- define technical terms
- clarify singular and plural forms
- explain "at least" phrase
- define "comprise" and variations
- explain "consisting of" and "consisting essentially of"
- define "and/or" conjunctive term
- clarify numerical values with "about"
- define "% sequence identity" for amino acid sequences
- explain "in combination" and related phrases
- define "non-naturally occurring" nucleic acid or polypeptide
- define "subject" and "mammal"
- explain "operably linked" components
- introduce hepatitis B virus (HBV) and its components

### HBV Antigens

- define HBV antigen
- describe HBV core antigen
- motivate truncated HBV core antigen
- describe consensus sequence
- define consensus antigen
- describe HBV polymerase antigen
- motivate inactivated HBV Pol antigen
- describe modifications to improve immunogenicity
- describe fusion protein
- motivate fusion of HBV core antigen and HBV polymerase antigen
- describe exemplary fusion protein
- define linker
- describe fusion protein
- specify fusion protein components
- define HBV surface antigen
- describe HBV surface antigen types
- specify S-surface antigen
- specify M-surface antigen
- specify L-surface antigen
- describe HBV surface antigen combinations
- provide exemplary HBV surface antigen sequences

### Polynucleotides and Vectors

- define non-naturally occurring nucleic acid molecule
- describe polynucleotide encoding HBV antigen
- specify polynucleotide forms
- describe truncated HBV core antigen
- describe HBV polymerase antigen
- describe fusion protein
- describe S-surface antigen
- describe HBV surface antigen
- provide examples of polynucleotide sequences
- define polynucleotides and vectors
- describe HBV surface antigen encoding polynucleotides
- introduce vectors for HBV antigen expression
- explain expression vectors and their design
- describe non-viral vectors and their components
- introduce DNA plasmids as non-viral vectors
- describe viral vectors and their components
- introduce adenovirus vectors as viral vectors
- explain codon-optimization of polynucleotides
- describe regulatory elements in vectors
- explain expression cassettes and their components
- list promoters
- describe CMV-IE promoter
- list polyadenylation signals
- describe bGH polyadenylation signal
- list enhancer sequences
- describe triple enhancer sequence
- describe signal peptide sequences
- describe cystatin S signal peptide
- describe bacterial origin of replication
- describe antibiotic resistance expression cassette
- describe kanamycin resistance gene
- describe codon optimized Kanr gene
- describe plasmid vector
- describe expression cassette
- describe viral vector
- describe adenoviral vector
- describe vector construction

### Cells, Polypeptides and Antibodies

- provide cells comprising polynucleotides and vectors
- describe method of making HBV antigen
- define recombinant polypeptides with HBV antigen sequences
- describe antibodies specific to non-naturally occurring polypeptides
- define antibody specificity and affinity

### Compositions, Immunogenic Combinations, and Vaccines

- relate to compositions
- describe composition components
- specify truncated HBV core antigen
- specify HBV polymerase antigen
- specify HBV surface antigen
- specify S-surface antigen
- describe vector compositions
- specify vector components
- describe fusion protein compositions
- specify isolated truncated HBV core antigen
- specify isolated HBV polymerase antigen
- specify isolated HBV surface antigen
- specify isolated S-surface antigen
- relate to immunogenic combinations or kits
- describe immunogenic combination components
- specify first non-naturally occurring nucleic acid molecule
- specify second non-naturally occurring nucleic acid molecule
- define compositions, immunogenic combinations, and vaccines
- describe polynucleotides and vectors
- outline embodiments of immunogenic combinations or kits
- detail first and second polynucleotides in separate vectors
- describe first and second polynucleotides in same vector
- outline embodiments with third and fourth polynucleotides
- describe third and fourth polynucleotides in separate vectors
- detail third and fourth polynucleotides in same vector
- outline embodiments with additional polynucleotides or vectors
- define anti-HBV agents
- describe pharmaceutically acceptable carriers
- outline routes of administration
- describe formulation for parenteral injection
- detail buffered solution in pharmaceutically acceptable carrier
- outline DNA vaccine formulation
- describe RNA vaccine formulation
- outline adjuvants for co-administration or inclusion
- describe anti-HBV agents as adjuvants
- outline methods of making compositions and immunogenic combinations
- describe mixing isolated polynucleotides with pharmaceutically acceptable carriers
- outline conventional techniques for preparing compositions
- describe optional inclusion of adjuvants
- summarize methods of making compositions and immunogenic combinations

### Methods of Inducing an Immune Response

- define infection
- define HBV infection
- describe inducing an immune response
- describe therapeutic immunity
- describe protective immunity
- describe administration of compositions
- define immunogenically effective amount
- describe effects of immunogenically effective amount
- provide examples of immunogenically effective amount
- describe prime-boost regimen
- describe administration of multiple plasmids
- describe ratio of plasmids
- describe chronic HBV infection
- describe phases of chronic HBV infection
- describe treatment of chronic HBV infection

### Methods of Delivery

- describe administration methods
- describe parenteral administration
- describe electroporation
- describe transdermal administration
- describe other methods of intracellular delivery

### Adjuvants

- define adjuvants
- list examples of adjuvants
- describe administration of adjuvants
- list anti-HBV agents for combination therapy

### Methods of Prime/Boost Immunization

- describe prime-boost regimen
- illustrate prime-boost regimen example

### Kits

- define kit composition
- describe kit components
- specify polynucleotide sequences
- detail adjuvants and immune stimulants
- outline evaluation methods for immune response
- describe measurement of cellular immunity
- detail antibody binding and competition
- outline ELISA and neutralizing antibody assays
- describe ADCP assay
- introduce embodiments section
- define embodiment 1
- specify embodiment 2
- detail embodiment 3
- describe embodiment 4
- outline embodiment 5
- specify embodiment 6
- detail embodiment 7
- describe embodiment 8
- outline embodiment 9
- define vaccine combinations
- specify polynucleotide sequences
- describe plasmid DNA vectors
- outline composition for inducing immune response
- outline composition for treating HBV-induced disease
- describe method of inducing immune response
- describe method of treating HBV-induced disease
- define non-naturally occurring nucleic acid molecules
- specify HBV surface antigens
- describe vectors comprising non-naturally occurring nucleic acid molecules
- specify plasmid DNA vector components
- define kits
- specify embodiment 16
- specify embodiment 17
- specify embodiment 18
- specify embodiment 19
- specify embodiment 20
- specify embodiment 21
- specify embodiment 22
- specify embodiment 23
- specify embodiment 24
- specify embodiments 25-46
- specify embodiment 47
- specify embodiment 48
- specify embodiments 49-50

## EXAMPLES

- introduce examples of the application

### Example 1: Generation of HBV Core and Pol Antigen Sequences and Plasmid Optimization

- derive HBV core and pol antigen consensus sequences
- optimize HBV core antigen
- optimize HBV pol antigen
- optimize HBV core and pol antigen expression strategies
- optimize post-transcriptional regulatory elements
- select signal peptide for efficient protein secretion
- optimize DNA vaccine vector

### Example 2: Generation of Adenoviral Vectors Expressing a Fusion of Truncated HBV Core Antigen with HBV Pol Antigen

- design expression cassettes for adenoviral vectors

### Example 3: In Vivo Immunogenicity Study of DNA Vaccine in Mice

- test DNA vaccine in mice
- analyze T-cell responses
- quantify antigen-specific responses
- evaluate immunogenicity of DNA vaccine

### Example 4: Dose-Finding Study of Combined pDK-Core/pDK-Pol Plasmids in Mice

- evaluate immune responses to combined plasmids
- determine optimal DNA dose

### Example 5: Immune Interference Study in Mice

- assess immune interference of combined plasmids

### Example 6: Evaluation of the Efficacy of a DNA Vaccine in Non-Human Primates

- introduce study purpose
- describe vaccine composition
- outline electroporation administration
- detail non-human primate subjects
- describe ELISPOT analysis
- describe intracellular cytokine staining (ICS)
- present results

### CONCLUSION

- summarize results

### Example 7: Evaluation of the Efficacy of a DNA Vaccine in Human Subjects

- introduce human subjects
- describe vaccine composition and administration
- outline evaluation of efficacy

### Example 8: In Vivo Immunogenicity Study of Adenoviral Vectors in Mice

- introduce study purpose
- describe adenoviral vectors
- outline in vivo immunogenicity study
- detail administration to F1 mice
- describe ELISPOT analysis
- present results
- summarize findings

